Skip to main content


Table 4 Small molecule inhibitors

From: Novel and emerging therapies for B cell lymphoma

DrugClassPatient populationNORRCRGrade 3 AEReference
M7583BTK inhibitorR/R DLBCL, WM, MCL, MZL, SLL1850%11%Diarrhea[80]
ME-401PI3KδR/R FL, CLL3183%NADiarrhea, rash[81]
LAM-002AEndosomal protein inhibitorR/R DLBCL, MCL, FL, MZL, CLL24NANATumor lysis syndrome[82]
INCB057643BET protein inhibitorR/R FL, DLBCL533% (DE)NoneHyperglycemia, thrombocytopenia, anemia, hyperbilirubinemia, Increased INR[83]
MRG-106miR-155 inhibitorMycosis fungoides38NANAPruritus, tumor flare[84]
DS-3201bEZH1/2 dual inhibitorPTL, AITL, DLBCL, FL, MZL1553%6.6%Pneumonia[85]
ApatinibVEGFR-2 tyrosine kinase inhibitorR/R NHL2147.6%9.5%None[86]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, AE adverse events, R/R relapsed and refractory, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MZL marginal zone lymphoma, MCL mantle cell lymphoma, PTL peripheral T cell lymphoma, AITL angio-immunoblastic T cell lymphoma, NHL non-Hodgkin lymphoma, VEGFR-2 vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, PI3Kδ phosphatidylinositol 3 kinase delta, BET bromodomain and extraterminal protein inhibitor, EZH enhancer of zeste homolog, miR micro RN, DE dose escalation phase, NA data unavailable